Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

UPDATE: Catalyst check off:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__18. Generate revenues over $20 million/quarter
__19. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__20. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__21. European distribution - Dexcel partnership approval by Israeli Health
__22. Full ownership of Adderall IR $ 335 Million
__23. Full ownership of Adderall XR $ 1.56 Billion
__24. Generic Concerta- $1.2 BILLION FDA submission
__25. $100 million in yearly revenue
__26. Generic Vyvanse Approval and Launch
__27. $200 million in yearly revenue
__28. Deep pocket partner for SequestOx
__29. Patented Unique ADF (w/o naltrexone)-- NDA
__30. Mikah ANDA (s)
__31. Undisclosed ANDAs/NDAs
__32. DollarLand PPS
__33. Uplist to the NASDAQ Exchange
__34. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__35. Vegas Baby !!!!!!!
X 36. PE below 8.